Antiviral Treatment for CMV Eye Inflammation
Treatments studied
Part of Eyes & vision, Infections clinical trials.
This trial tests antiviral medications (pills and eye drops) to treat and prevent a viral eye inflammation caused by cytomegalovirus (CMV). The study has two parts: one for newly diagnosed active inflammation, and another to prevent flare-ups in people who've already had CMV eye inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (or 20 in Thailand/Taiwan)
- For Trial I: active eye inflammation with CMV confirmed by a fluid test from your eye
- For Trial II: prior confirmed CMV eye inflammation and currently calm/inactive inflammation
- You must be willing to use contraception during and for 30–90 days after the study medication
- You cannot have a weakened immune system, severe blood counts, or kidney/liver problems
- You cannot be pregnant, breastfeeding, or allergic to antiviral drugs like ganciclovir or acyclovir
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This trial tests a study drug called artesunate as a possible new treatment for CMV (a common virus) in people who have had a kidney, lung, heart, or liver transplant. It is for patients whose CMV infection requires treatment with standard antivirals like ganciclovir or valganciclovir.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.